At Rhythm, we are dedicated to discovering therapies for rare neuroendocrine diseases.
Our science is focused on developing therapies for patients with hyperphagia (insatiable hunger) and obesity caused by an impaired melanocortin-4 receptor (MC4R) pathway. We are also investigating treatments for other rare diseases, including congenital hyperinsulinism.
The MC4R pathway
Diseases caused by MC4R pathway impairments manifest with hyperphagia and result from rare gene variants and/or injury to the hypothalamus, distinct from more common causes of obesity.
Our areas of focus
We are developing therapies to reestablish the function of the MC4R pathway to treat certain rare diseases, including Bardet-Biedl syndrome, acquired hypothalamic obesity, and additional MC4R pathway diseases.
Our approach to developing treatments is built upon our foundational understanding of genetics.
